Skip to main navigation
  • Home

  • Development Programs

  • VX15 Immuno-Oncology

  • VX15 Neurology

  • VX18 Neurology

  • VX15 Autoimmune

  • NKT Vaccine

  • NKT Vaccine

  • ActivMAb®

  • Vaccinia Display

  • Capabilities

  • Optimization

  • Target Identification

  • Publications

  • News & Publications

    • News

    • Publications

  • Careers

  • Corporate

    • Management

    • Partners

    • Contact

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Home

  • About

  • Corporate Overview

  • Management

  • Partners

  • Pipeline

  • Pepinemab
    Neurology

  • Pepinemab
    Immuno-Oncology

  • Research & Development Programs

  • Clinical Trials

  • Patients

  • Physicians & Researchers

  • News & Publications

    • News

    • Publications

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Careers

  • Contact Us

  • ActivMAb ®

    • Vaccinia

    • Antibody Discovery

    • Antigen Virus

    • Protein Optimization

    • Antigen Discovery

    • Antibody Optimization

    • ActivMAb ® Contact

Science in the service of medicine
  • About
    • Corporate Overview
    • Management
    • Partners
  • Pipeline
    • Pepinemab Neurology
    • Pepinemab Immuno-Oncology
    • Research & Development Programs
  • Clinical Trials
    • Patients
    • Physicians & Researchers
  • News & Publications
    • News
    • Publications
  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events
  • Presentations
  • Careers
  • Contact Us
  • ActivMAb ®
    • Vaccinia
    • Antibody Discovery
    • Antigen Virus
    • Protein Optimization
    • Antigen Discovery
    • Antibody Optimization
    • Contact Us

Investors

  • Investor Overview
  • News Releases
  • Events
  • Presentations
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Investor Services

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts
  • LinkedIn
  • Twitter

Filter by content type

  • (-) News (19)

Filter by form group

Filter by year

  • (-) 2019 (19)
News

Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 12, 2019 - … enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion … expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study at the Society for Immunotherapy of …
News

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update

August 14, 2019 - … enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion … in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical …
News

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 9, 2019 - … Combination with Avelumab (BAVENCIO(R)) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for … from the poster presentation. Updated Interim Data The CLASSICAL-Lung trial is being conducted in collaboration with … of the Company's website, www.vaccinex.com . About the CLASSICAL - Lung Clinical Trial The design of the trial …
News

Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program

November 14, 2019 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
News

Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 15, 2019 - … Update 05/15/19 Earnings Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the … results from the dose escalation phase of the ongoing CLASSICAL-Lung Phase 1b/2 study at the American Association …
News

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France

September 27, 2019 - … Combination with Avelumab (BAVENCIO(R)) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth … for Cancer Research (AACR). Updated Interim Data The CLASSICAL-Lung trial is being conducted in collaboration with … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
News

Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer

August 13, 2019 - … Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with … … Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination …
News

Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)

April 9, 2019 - … Research (AACR) 04/09/19 General First Interim Results of CLASSICAL-Lung Phase 1b/2 Study Demonstrate Up To 90 Percent Disease … The company presented interim data for its Phase 1b/2 CLASSICAL-Lung study of its pepinemab antibody in combination …
News

Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting

June 3, 2019 - … Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting … Vaccinex … of the presentation, presented "Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) … the many subject volunteers and clinicians involved in the CLASSICAL-Lung clinical trial with whom we share a hope for …
News

Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation

December 10, 2019 - … and our collaboration with Merck KGaA in Non-Small Cell Lung Cancer could bring important benefits to our patients … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in … and our collaboration with Merck KGaA in Non-Small Cell Lung Cancer could bring important benefits to our patients …

Pagination

  • Page 1
  • Next page ››

  • About
  • Pipeline
  • Clinical Trials
  • News
  • Careers
  • Contact
Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com
  • © 2022 Vaccinex. All rights reserved
  • |
  • Privacy Policy
  • |
  • Site by Minerva